title: A rapid non invasive L-DOPA-¹³C breath test for optimally suppressing extracerebral AADC enzyme activity - toward individualizing carbidopa therapy in Parkinson’s disease.
abstract: BACKGROUND
  Peripheral carbidopa (CD) levels directly impact on central dopamine (DA) production in Parkinson disease (PD) through extracerebral inhibition of dopa decarboxylase (AADC) resulting in an increase in levodopa (LD) bioavailability.
  
  
  OBJECTIVE
  Recent data suggests that higher CD doses than those presently used in PD treatment may result in improved clinical response. Optimizing CD doses in individual patients may, therefore, result in ideal individualized treatment.
  
  
  METHODS
  A single center, randomized, double-blind study was carried out recruiting 5 Parkinson’s disease (PD) patients already on LD/CD and 1 treatment näve PD patient using stable isotope labeled LD-1-¹³C as a substrate for a noninvasive breath test to evaluate individual AADC enzyme activity. Each patient was studied five times, receiving 200 mg LD-¹³C at each visit along with one of five randomized CD doses (0, 25, 50, 100 and 200 mg). The metabolite ¹³CO₂ in breath was measured for evaluating AADC enzyme activity and plasma metabolite levels for LD-¹³C and homovanillic acid (HVA) were measured for 4 hours.
  
  
  RESULTS
  HVA in plasma and ¹³CO₂ in breath are metabolic products of LD. We found a significant positive correlation of ¹³CO₂ DOB AUC0-240 with serum HVA AUC0-240 following the oral dose of LD-1-¹³C for all 5 doses of CD (r² = 0.9378). With increasing inhibition of AADC enzyme activity with CD, we observed an increase in the plasma concentration of LD.We found an inverse correlation of the 13CO2 DOB AUC with serum LD-¹³C AUC. Our studies indicate the optimal dose of CD for maximal suppression of AADC enzyme activity can be determined for each individual from ¹³CO₂ generation in breath.
  
  
  CONCLUSIONS
  The LD-breath test can be a useful noninvasive diagnostic tool for evaluation of AADC enzyme activity using the biomarker ¹³CO₂ in breath, a first step in personalizing CD doses for PD patients.
authors: Cambridge Isotope Laboratories Inc., Andover, MA 01830, USA. anilm@isotope.com
authors: Anil
authors: A
authors: Modak
authors: Raymon
authors: R
authors: Durso
authors: Ephraim
authors: E
authors: Josephs
authors: David
authors: D
authors: Rosen
mesh_terms: D001921:Brain / Q000378:metabolism; D002230:Carbidopa / Q000627:therapeutic use*; D004296:Dopa Decarboxylase / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000032:analysis* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D007980:Levodopa; D004296:Dopa Decarboxylase; D002230:Carbidopa; D004298:Dopamine
references: Br J Clin Pharmacol. 1997 Jul;44(1):41-8
references: 9241095
references: J Pharmacol Exp Ther. 2009 Apr;329(1):297-305
references: 19136640
references: J Clin Pharmacol. 2000 Aug;40(8):854-60
references: 10934669
references: J Clin Invest. 1971 Dec;50(12):2734-40
references: 5129321
references: Neurology. 1992 Nov;42(11):2111-7
references: 1436520
references: World J Gastroenterol. 2009 Feb 28;15(8):966-72
references: 19248196
references: J Neurochem. 1982 Feb;38(2):380-5
references: 7108544
references: Br J Clin Pharmacol. 2002 Oct;54(4):363-71
references: 12392583
references: Clin Cancer Res. 2006 Sep 15;12(18):5491-5
references: 17000684
references: Br Med J. 1971 Sep 25;3(5777):729-32
references: 4938431
references: Ann Neurol. 1996 May;39(5):561-73
references: 8619540
references: Ann Neurol. 1987 Oct;22(4):475-9
references: 3435068
references: Ann Neurol. 1997 Sep;42(3):300-4
references: 9307250
references: Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S49-51
references: 22166453
references: Ann Neurol. 1987 Apr;21(4):370-6
references: 3579222
references: N Engl J Med. 1984 Feb 23;310(8):483-8
references: 6694694
references: N Engl J Med. 2004 Dec 9;351(24):2498-508
references: 15590952
references: J Cereb Blood Flow Metab. 2011 Jan;31(1):124-31
references: 20407462
references: Mov Disord. 2012 May;27(6):750-3
references: 22508376
references: Ann Neurol. 2003;53 Suppl 3:S3-12; discussion S12-5
references: 12666094
references: J Neurol. 2009 Dec;256(12):1972-6
references: 19575260
references: Neurology. 1987 Jun;37(6):940-4
references: 3587644
references: J Neural Transm (Vienna). 2007 Sep;114(9):1147-53
references: 17446998
references: J Clin Pharmacol. 2008 Sep;48(9):1041-51
references: 18728242
references: Ann Neurol. 1985 Nov;18(5):537-43
references: 4073849
references: J Nucl Med. 1992 Aug;33(8):1472-7
references: 1634937
references: J Pharmacol Exp Ther. 1995 Jun;273(3):1323-31
references: 7791104
references: Biochem Pharmacol. 1981 Mar 15;30(6):645-9
references: 7271902
references: Clin Cancer Res. 2004 Apr 15;10(8):2652-8
references: 15102667
references: J Chromatogr. 1988 Aug 19;430(1):112-7
references: 3215947
references: Curr Neurol Neurosci Rep. 2002 Jul;2(4):310-6
references: 12044250